

## ROMOSOZUMAB solution for injection (EVENTITY® ▼) for treatment of severe osteoporosis in postmenopausal women

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ROMOSOZUMAB solution for injection (EVENTITY® ▼) for treatment of severe osteoporosis in postmenopausal women.**

### GREY

Romosozumab is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.<sup>1</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of severe osteoporosis in postmenopausal women should continue to follow national guidance and local formulary choices:

- > NICE Pathway [Osteoporosis overview](#) (updated 06 April 2020)
- > NICE Quality Standard QS 149 [Osteoporosis](#) (28 April 2017)
- > National Osteoporosis Guideline Group [NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis](#) (updated July 2019)
- > Pan Mersey APC Formulary [Bisphosphonates and other drugs affecting bone metabolism, Teriparatide, Raloxifene](#)

### References

1. UCB Pharma Limited. Summary of Product Characteristics; [EVENTITY 105 mg solution for injection in pre-filled pen](#), 9 December 2019. Accessed online 05 May 2020.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.